Literature DB >> 1490760

High volume plasma exchange in fulminant hepatic failure.

J Kondrup1, T Almdal, H Vilstrup, N Tygstrup.   

Abstract

We investigated the effect of repeated high volume plasma exchange with fresh donor plasma in 11 patients with fulminant hepatic failure, all initially in stage 3 or 4 encephalopathy. A daily exchange of a volume equal to the extracellular volume (20% of body weight) on three consecutive days was intended. We obtained an average of 2.6 exchanges each with a mean volume equal to 16% of the body weight. Five patients (46%, 95% confidence limits 17%-77%) survived, all with acetaminophen induced liver failure. Four of the 6 non-survivors showed a temporary improvement in cerebral function. Two of the patients woke up completely. The 6 non-survivors maintained a stable condition with a systolic blood pressure > 110 mm Hg for a mean of 6.9 days after initiating plasma exchange. Plasma exchange may be considered in acute liver failure in patients with residual liver function before transplantation is finally decided. In addition, plasmapheresis may be used to keep patients with definite liver failure clinically stable until a transplant can be performed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1490760

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  15 in total

1.  Fulminant Hepatic Failure.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-04

2.  Prognosis of acute-on-chronic liver failure patients treated with artificial liver support system.

Authors:  Pi-Qi Zhou; Shao-Ping Zheng; Min Yu; Sheng-Song He; Zhi-Hong Weng
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

Review 3.  Efficacy of liver assisting in patients with hepatic encephalopathy with special focus on plasma exchange.

Authors:  Poul Stenbøg; Troels Busk; Fin Stolze Larsen
Journal:  Metab Brain Dis       Date:  2013-04-10       Impact factor: 3.584

Review 4.  Current state of knowledge of hepatic encephalopathy (part IV): Management of Hepatic Encephalopathy by liver support systems.

Authors:  Tarek Hassanein
Journal:  Metab Brain Dis       Date:  2016-12-24       Impact factor: 3.584

5.  Role of plasmapheresis in the management of acute hepatic failure in children.

Authors:  A L Singer; K M Olthoff; H Kim; E Rand; G Zamir; A Shaked
Journal:  Ann Surg       Date:  2001-09       Impact factor: 12.969

6.  Changes in peripheral CD4+CD25(high) regulatory T cells in the acute-on-chronic liver failure patients with plasma exchange treatment.

Authors:  Wei-lin Mao; Yu-Feng Lou; Bo Ye; Sha Lin; Yue-mei Chen; Yu Chen
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

7.  Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure.

Authors:  Achilles A Demetriou; Robert S Brown; Ronald W Busuttil; Jeffrey Fair; Brendan M McGuire; Philip Rosenthal; Jan Schulte Am Esch; Jan Lerut; Scott L Nyberg; Mauro Salizzoni; Elizabeth A Fagan; Bernard de Hemptinne; Christoph E Broelsch; Maurizio Muraca; Joan Manuel Salmeron; John M Rabkin; Herold J Metselaar; Daniel Pratt; Manuel De La Mata; Lawrence P McChesney; Gregory T Everson; Philip T Lavin; Anthony C Stevens; Zorina Pitkin; Barry A Solomon
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

Review 8.  Clinical application of bioartificial liver support systems.

Authors:  Maarten Paul van de Kerkhove; Ruurdtje Hoekstra; Robert A F M Chamuleau; Thomas M van Gulik
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

9.  Acute liver failure: Summary of a workshop.

Authors:  William M Lee; Robert H Squires; Scott L Nyberg; Edward Doo; Jay H Hoofnagle
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

Review 10.  Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.

Authors:  Mitra K Nadim; John A Kellum; Andrew Davenport; Florence Wong; Connie Davis; Neesh Pannu; Ashita Tolwani; Rinaldo Bellomo; Yuri S Genyk
Journal:  Crit Care       Date:  2012-02-09       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.